Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety - PubMed (original) (raw)

Review

Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety

Meredith Noble et al. J Pain Symptom Manage. 2008 Feb.

Free article

Abstract

Opioid therapy for chronic noncancer pain (CNCP) is controversial due to concerns regarding long-term efficacy and adverse events (including addiction). We systematically reviewed the clinical evidence on patients treated with opioids for CNCP for at least six months. Of 115 studies identified by our search of eleven databases (through April 7, 2007), 17 studies (patients [n]=3,079) met inclusion criteria. Studies evaluated oral (studies [k]=7; n=1,504), transdermal (k=3; n=1, 993), and/or intrathecal (k=8; n=177) opioids. Many patients withdrew from the clinical trials due to adverse effects (oral: 32.5% [95% confidence interval (CI), 26.1%-39.6%]; intrathecal: 6.3% [95% CI, 2.9%-13.1%]; transdermal: 17.5% [95% CI, 6.5%-39.0%]), or due to insufficient pain relief (oral: 11.9% [95% CI, 7.8%-17.7%]; intrathecal: 10.5% [95% CI, 3.5%-27.4%]; transdermal: 5.8% [95% CI, 4.2%-7.3%]). Signs of opioid addiction were reported in only 0.05% (1/2,042) of patients and abuse in only 0.43% (3/685). There was an insufficient amount of data on transdermal opioids to quantify pain relief. For patients able to remain on oral or intrathecal opioids for at least six months, pain scores were reduced long-term (oral: standardized mean difference [SMD] 1.99, 95% CI, 1.17-2.80; intrathecal: SMD 1.33, 95% CI, 0.97-1.69). We conclude that many patients discontinue long-term opioid therapy due to adverse events or insufficient pain relief; however, weak evidence suggests that oral and intrathecal opioids reduce pain long-term in the relatively small proportion of individuals with CNCP who continue treatment.

PubMed Disclaimer

Cited by

Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials.
Marcucci M, Germini F, Coerezza A, Andreinetti L, Bellintani L, Nobili A, Rossi PD, Mari D. Marcucci M, et al. Trials. 2016 Jul 29;17:369. doi: 10.1186/s13063-016-1496-9. Trials. 2016. PMID: 27473188 Free PMC article. Clinical Trial.
Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.
Webster LR, Israel RJ. Webster LR, et al. J Pain Res. 2018 Aug 13;11:1503-1510. doi: 10.2147/JPR.S160488. eCollection 2018. J Pain Res. 2018. PMID: 30147355 Free PMC article.
Prevalence of Therapeutic use of Opioids in Chronic non-Cancer Pain Patients and Associated Factors: A Systematic Review and Meta-Analysis.
De Sola H, Dueñas M, Salazar A, Ortega-Jiménez P, Failde I. De Sola H, et al. Front Pharmacol. 2020 Nov 18;11:564412. doi: 10.3389/fphar.2020.564412. eCollection 2020. Front Pharmacol. 2020. PMID: 33364942 Free PMC article. Review.
Factors Associated With Interest in Engaging in Psychological Interventions for Pain Management.
Miller-Matero LR, Yaldo M, Chohan S, Zabel C, Patel S, Chrusciel T, Salas J, Wilson L, Sullivan MD, Ahmedani BK, Lustman PJ, Scherrer JF. Miller-Matero LR, et al. Clin J Pain. 2024 Feb 1;40(2):67-71. doi: 10.1097/AJP.0000000000001165. Clin J Pain. 2024. PMID: 37819213

Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety - PubMed (original) (raw)